Fresenius Infringes Sanofi's Eloxatin Patent: Judge

By Abigail Rubenstein

Law360, New York (March 15, 2010, 3:43 PM ET) -- Sanofi-Aventis US LLC has won summary judgment of infringement against Fresenius Kabi Pharma Ltd., scoring a victory in its bid to keep generic versions of popular colon cancer drug Eloxatin off the market.

Judge Joel Pisano of the U.S. District Court for the District of New Jersey on Friday granted summary judgment to Sanofi, ruling that Fresenius' proposed generic infringes the patent for Eloxatin.

The patent covers a chemical compound for “optically pure oxaliplatin,” the active ingredient in Eloxatin, and Judge Pisano's ruling hinged on the...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles